GlassScriptPhysician profile
Yimei You
NPI 1487909339
$6,945.85
in general payments reported to CMS, 2019-2025
46 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $196 · 2022: $654 · 2023: $1,307 · 2024: $1,848 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,848 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,848.11 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,040.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $906.62 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $651.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $359.67 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $346.41 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $330.45 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $325.06 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $279.13 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $266.80 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.74 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $201.78 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $191.89 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $161.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $158.18 | 2019-2025 | Verquvo, Lagevrio |
| Glaxosmithkline, LLC. | $147.96 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $110.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $103.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $96.65 | 2019-2022 | |
| Eisai INC. | $75.72 | 2023-2024 | |
| Dexcom, INC. | $73.32 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $73.16 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.90 | 2022-2025 | Caplyta |
| Almatica Pharma LLC | $72.60 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Azurity Pharmaceuticals, INC. | $67.75 | 2024-2025 | Horizant, Edarbi |
| Daiichi Sankyo INC. | $64.94 | 2019-2025 | Injectafer |
| Allergan, INC. | $61.25 | 2019-2020 | |
| Lundbeck LLC | $56.61 | 2022-2024 | Rexulti |
| Amgen INC. | $43.99 | 2019-2025 | Evenity, Prolia, Prolia |
| Vanda Pharmaceuticals INC. | $40.90 | 2019-2025 | Fanapt |
| Alkermes, INC. | $37.37 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Nevro Corp. | $31.50 | 2023 | Senza |
| Ibsa Pharma INC. | $30.83 | 2019-2024 | Tirosint, Licart |
| Avanir Pharmaceuticals, INC. | $28.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.72 | 2019 | |
| Medtronic, INC. | $24.26 | 2024 | Intellis Adaptivestim |
| Abbvie INC. | $18.24 | 2025 | |
| Insmed, INC. | $17.68 | 2024 | Arikayce |
| Depuy Synthes Sales INC. | $17.40 | 2023 | Orthovisc, Monovisc |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.43 | 2025 | |
| Genentech USA, INC. | $15.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.86 | 2025 | Gvoke Hypopen |
| Hikma Pharmaceuticals USA | $13.28 | 2019 | |
| Acorda Therapeutics, INC | $13.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.00 | 2019 | |
| Sumitomo Pharma America, INC. | $12.54 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yimei You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.